Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?

Area of Science:

• Biomedical Science
• Genetics
• Therapeutics

Background:

• Mucopolysaccharidoses (MPSs) are lysosomal storage disorders (LSDs) requiring improved treatment strategies.
• Current therapies for MPSs offer partial success, potentially due to late intervention and limited protein efficacy.
• Newborn screening initiatives highlight the need for perinatal therapeutic approaches.

Purpose of the Study:

• To review advancements in neonatal cellular and gene-based therapies for MPSs.
• To identify barriers to implementing early-stage treatments for lysosomal storage disorders.
• To emphasize the critical role of precocious intervention in preventing long-term pathological consequences.

Main Methods:

• Review of existing literature on neonatal cellular and gene therapy approaches for MPSs.
• Analysis of animal model studies investigating early-stage treatment efficacy.
• Assessment of current therapeutic limitations and future implementation challenges.

Main Results:

• Neonatal cellular and gene therapies show promise in animal models for preventing long-term pathological consequences.
• Early intervention at birth is critical for mitigating disease progression in MPSs.
• Significant barriers remain for the clinical implementation of these neonatal therapies.

Conclusions:

• Precocious cellular and gene therapies during the perinatal period are essential for effective MPS treatment.
• Overcoming current barriers is necessary to translate neonatal therapeutic approaches into clinical practice.
• Further research and development are crucial for advancing newborn screening and early intervention for LSDs.